Novavax, Inc (NASDAQ:NVAX)’s traded shares stood at 0.53 million during the latest session, with the company’s beta value hitting 3.07. At the last check today, the stock’s price was $7.83, to imply a decrease of -1.01% or -$0.08 in intraday trading. The NVAX share’s 52-week high remains $23.86, putting it -204.73% down since that peak but still an impressive 51.34% since price per share fell to its 52-week low of $3.81. The company has a valuation of $1.26B, with an average of 3.73 million shares in intraday trading volume over the past 10 days and average of 4.33 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Novavax, Inc (NVAX), translating to a mean rating of 2.14. Of 16 analyst(s) looking at the stock, 0 analyst(s) give NVAX a Sell rating. 0 of those analysts rate the stock as Overweight while 6 advise Hold as 10 recommend it as a Buy.
Novavax, Inc (NASDAQ:NVAX) trade information
After registering a -1.01% downside in the latest session, Novavax, Inc (NVAX) has traded red over the past five days. The 5-day price performance for the stock is -4.16%, and -2.37% over 30 days. With these gigs, the year-to-date price performance is -2.61%. Short interest in Novavax, Inc (NASDAQ:NVAX) saw shorts transact 39.23 million shares and set a 9.02 days time to cover.
The extremes give us $14 and $25 for target low and target high price respectively. As such, NVAX has been trading -219.28% off suggested target high and -78.8% from its likely low.
Novavax, Inc (NVAX) estimates and forecasts
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 25.88% for the past 5-year period. While 2025 is set for a 81.77% return in earnings, projections for the next 5 years are at 67.92% annually.
NVAX Dividends
Novavax, Inc has its next earnings report out on 2025-Feb-26. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Novavax, Inc (NASDAQ:NVAX)’s Major holders
Novavax, Inc insiders hold 8.80% of total outstanding shares, with institutional holders owning 60.18% of the shares at 65.99% float percentage. In total, 60.18% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 14.08 million shares (or 10.0599% of shares), all amounting to roughly $178.19 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 11.85 million shares, or about 8.4669% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $149.98 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Novavax, Inc (NVAX) shares. Going by data provided on Dec 31, 2024 , Vanguard Total Stock Market Index Fund holds roughly 4.79 shares. This is just over 2.98% of the total shares, with a market valuation of $37.43 million. Data from the same date shows that the other fund manager holds a little less at 4.15, or 2.58% of the shares, all valued at about 32.47 million.
